Sequenom, IntegraGen, Ciphergen, Clinical Data | GenomeWeb
Sequenom Says Q3 Revenue Grows 43 Percent as LossNarrows; Firm Ups '06 Guidance
 
Sequenom’s third-quarter revenues increased 43 percent as R&D spending rose 16 percent and losses decreased by 16 percent, the company announced last week.
 
Total receipts for the three months ended Sept. 30 increased to $6.5 million from $4.6 million year over year.
 
R&D spending increased to $3 million from $2.6 million year over year.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.